SCHEMBL455596

SCHEMBL455596

N#Cc1cc(-c2oc(C(=O)N3CCNC(=O)C3)cc2-c2cccc(Cl)c2)ccc1F

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.37
PARP1 P09874 3/20 0.35
BRAF P15056 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
HSP90AA1 P07900 1/20 0.35
KDM4E B2RXH2 2/20 0.35
GAA P10253 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDE4D Q08499 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SCN9A Q15858 1/20 0.34
TBK1 Q9UHD2 1/20 0.33
NTRK1 P04629 1/20 0.33
LRRK2 Q5S007 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PAK4 O96013 1/20 0.33
FFAR2 O15552 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL415848 0.92 KDM4E (0.36) PDE4BBRAFKDM4EGAAPDE4D
SCHEMBL416921 0.90 PDE4B (0.40) PDE4BPARP1BRAFPARP2HSP90AA1
SCHEMBL417650 0.89 HSP90AA1 (0.40) PDE4BPARP1BRAFPARP2HSP90AA1
SCHEMBL460246 0.89 EIF4A3 (0.40) PDE4BPARP1BRAFHSP90AA1GAA
SCHEMBL419600 0.89 PDE4B (0.44) PDE4BPARP1BRAFHSP90AA1GAA
SCHEMBL421343 0.87 PGR (0.39) PDE4BPARP1PARP2HSP90AA1GAA
SCHEMBL417594 0.87 PDE4B (0.38) PDE4BPARP1BRAFPARP2HSP90AA1
SCHEMBL421281 0.87 PDE4B (0.41) PDE4BPARP1BRAFPARP2HSP90AA1
SCHEMBL418626 0.86 PDE4B (0.41) PDE4BPARP1PARP2HSP90AA1GAA
SCHEMBL418318 0.85 PDE4B (0.41) PDE4BPARP1BRAFPARP2HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT PDE4B 1900/4885PARP1 1841/4885BRAF 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.